Trevena, Inc. (TRVN) Scheduled to Post Quarterly Earnings on Wednesday
Trevena, Inc. (NASDAQ:TRVN) is set to issue its quarterly earnings data before the market opens on Wednesday, November 1st. Analysts expect the company to announce earnings of ($0.33) per share for the quarter.
Trevena (NASDAQ:TRVN) last posted its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.35) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.35). On average, analysts expect Trevena to post $-1.27 EPS for the current fiscal year and $-0.76 EPS for the next fiscal year.
Trevena, Inc. (NASDAQ TRVN) opened at 1.54 on Wednesday. The company has a 50 day moving average price of $2.35 and a 200-day moving average price of $2.63. The firm’s market capitalization is $91.93 million. Trevena, Inc. has a 1-year low of $1.51 and a 1-year high of $8.00.
ILLEGAL ACTIVITY WARNING: This story was first published by American Banking News and is the property of of American Banking News. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.americanbankingnews.com/2017/10/25/trevena-inc-trvn-scheduled-to-post-quarterly-earnings-on-wednesday.html.
An institutional investor recently raised its position in Trevena stock. California State Teachers Retirement System boosted its stake in shares of Trevena, Inc. (NASDAQ:TRVN) by 0.5% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 97,107 shares of the biopharmaceutical company’s stock after purchasing an additional 500 shares during the quarter. California State Teachers Retirement System owned 0.16% of Trevena worth $223,000 at the end of the most recent quarter. 60.09% of the stock is owned by institutional investors.
Trevena Company Profile
Trevena Inc is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers.
Receive News & Ratings for Trevena Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena Inc. and related companies with MarketBeat.com's FREE daily email newsletter.